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Immunotherapy has transformed advanced non-small cell lung cancer
(NSCLC) treatment strategies and has led to unprecedented long-lasting
responses in some patients. However, the molecular determinants driving
these long-term responses remain elusive. To address this issue, we per-
formed an integrative analysis of genomic and transcriptomic features of
long-term immune checkpoint inhibitors (ICIs)-associated responders. We
assembled a cohort of 47 patients with NSCLC receiving ICIs that was
enriched in long-term responders [>18 months of progression-free survival
(PFS)]. We performed whole-exome sequencing from tumor samples, esti-
mated the tumor mutational burden (TMB), and inferred the somatic copy
number alterations (SCNAs). We also obtained gene transcription data for
a subset of patients using Nanostring, which we used to assess the tumor
immune infiltration status and PD-L1 expression. Our results indicate that
there is an association between TMB and benefit to ICIs, which is driven
by those patients with long-term response. Additionally, high SCNAs bur-
den is associated with poor response and negatively correlates with the
presence of several immune cell types (B cells, natural killers, regulatory T
cells or effector CD8 T cells). Also, CD274 (PD-L1) expression is increased
in patients with benefit, mainly in those with long-term response. In our
cohort, combined assessment of TMB and SCNAs burden enabled identifi-
cation of long-term responders (considering PFS and overall survival).
Notably, the association between TMB, SCNAs burden, and PD-L1
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expression with the outcomes of ICIs treatment was validated in two public
datasets of ICI-treated patients with NSCLC. Thus, our data indicate that
TMB is associated with long-term benefit following ICIs treatment in
NSCLC and that TMB, SCNAs burden, and PD-L1 are complementary
determinants of response to ICIs.
1. INTRODUCTION
Lung cancer is the world’s leading cause of cancer-re-
lated deaths due to its high incidence and low survival.
Fortunately, immune checkpoint inhibitors (ICIs),
antibodies that block programmed death 1 (PD1)
receptor or its ligand programmed death-ligand 1 (PD-
L1), have shown great efficacy leading to responses of
unprecedented duration in some patients [1–4]. Never-
theless, the majority of patients fail to respond to this
type of immunotherapy, and many that do eventually
develop resistance [5]. Therefore, the identification and
validation of biomarkers of ICIs response, and specifi-
cally of sustained benefit, are highly relevant to the
management of NSCLC patients.
Assessment of PD-L1 expression by immunohisto-
chemistry is the only validated test for ICIs first-line
treatment decisions in NSCLC [6,7]. Additionally, PD-
L1 expression has been recently associated with long-
term response to pembrolizumab, an anti-PD-1 drug
[8]. However, PD-L1 determination presents limita-
tions such as analysis variability or intra-tumor hetero-
geneity. Moreover, favorable responses to ICIs in
patients with no apparent expression of PD-L1 have
also been observed. Hence, there is a need to find
additional biomarkers or combinations of them to bet-
ter predict response. In this direction, the quantitative
analysis of the presence of different immune cell types
infiltrated within the tumor, which can be inferred
from gene transcriptional data, has been shown to be
indicative of benefit [9–13].
Tumor mutational burden (TMB) has also been
associated with ICIs response in several tumor types
such as melanoma and lung cancer [10,14,15]. Concep-
tually, a higher number of somatic mutations increase
the amount of potentially immunogenic neoantigens
that could be recognized by the adaptive immune sys-
tem. Nevertheless, the association between TMB and
ICIs response has not been observed in other tumor
types such as renal cell carcinoma [16]. Moreover, the
suitability of TMB as biomarker of ICIs response,
especially in melanoma, has been questioned [17,18]. A
less explored feature in relation to ICIs is the tumor’s
somatic copy number alterations (SCNAs) burden. In
melanoma, high levels of aneuploidy (SCNAs encom-
passing whole chromosome arms or entire chromo-
somes) or an overall increase of SCNAs burden were
associated with poorer response to ICIs [17,19], which
could be explained by the fact that highly aneuploid
tumors exhibit lower levels of immune-related tran-
scriptional signatures [19]. Conversely, TMB does not
seem to correlate with tumor immune infiltration, nor
with SCNAs burden or PD-L1 [8,11,20]. Therefore,
models combining TMB and PD-L1 expression or
immune-related signatures have been shown to better
predict response to ICIs [11,20].
Nevertheless, most efforts have been directed toward
identifying biomarkers of ICIs response, that is dur-
able clinical benefit (PFS > 6 months), while studies
assessing their value in predicting long-term benefit are
scarce, owing to the lack of long-lasting clinical fol-
low-up and the low representation of long-term
responders in unselected cohorts. Moreover, studies
often focus on just one or two biomarkers. Thus, there
is a need for integrative studies analyzing multiple
molecular biomarkers in the same set of individuals
presenting prolonged response to understand ICI-asso-
ciated long-term benefit. Here, we gathered a cohort of
ICI-treated patients with advanced NSCLC, some of
whom exhibited outstanding long-term responses to
these therapies, and assessed tumor-intrinsic genomic
biomarkers and extrinsic biomarkers (immune infiltra-
tion) to study their interplay and utility to discern ICIs
response and long-term benefit. Finally, we validated
our findings in two publicly available independent
cohorts [14,20].
2. Materials and methods
2.1. Patients data
All patients included in our cohort were diagnosed
with advanced NSCLC and treated at the Vall
d’Hebron Hospital. Written informed consent was
obtained from all patients before enrollment and the
Hospital Institutional Review Board approved this
study (PR(AG)139/2014). The study methodologies
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conformed to the standards set by the Declaration of
Helsinki. Detailed clinical information regarding the
cohort and each patient can be found in Tables S1
and S2. Archive tumor samples were obtained prior to
ICIs treatment. Patients were retrospectively collected.
2.2. Whole-exome sequencing
Whole-exome sequencing was performed on DNA
extracted from formalin-fixed paraffin-embedded
(FFPE) tumor samples (Maxwell 16 FFPEPlus LEV
DNA Purification Kit, Promega, Madison, WI, USA)
in addition to freshly obtained peripheral blood or
normal tissue. WES Libraries were prepared according
to manufacturer’s protocol (SureSelect XT Human All
Exon v5, Agilent, Santa Clara, CA, USA). Finally,
libraries were sequenced in a HiSeq2500 (Illumina, San
Diego, CA, USA), 2X100 Paired-end. Reads were
aligned against the hg19 reference genome.
2.3. Mutation calling
Mutation calling and subsequent filtering were per-
formed using the Mutect2-GATK pipeline [21]. During
the filtering process, cross-sample contamination was
assessed. Those samples with a percentage of cross-
sample contamination greater than 1% were discarded.
Resulting mutations were annotated using ANNO-
VAR [22].
2.4. SCNAs calling
Given the difficulties of estimating SCNAs from WES
data, SCNAs assessment was performed using two
independent methods: CNVkit [23] and Sequenza [24].
CNVkit was run providing the tumor purity estimated
by the pathologist as input. In the case of Sequenza,
sample purity was estimated by the tool itself. Only
regions found to bear SCNAs alterations by both
methods were considered for further analysis. Addi-
tionally, due to the limitations of assessing SCNAs in
low purity samples, those with an estimated tumor
purity by Sequenza of < 20 and a tumor purity
assessed by the pathologist of < 40 were discarded.
2.5. TMB and SCNAs burden
Tumor mutational burden was computed as the sum
of all exonic nonsynonymous mutations, insertions,
and deletions per sample.
SCNAs burden per patient was computed as the
sum of the sizes of all genomic regions affected by
SCNAs.
2.6. Gene expression assessment
Gene expression by Nanostring was carried out as pre-
viously described in Prat et al [13,25]. In fact, 8 out of
22 samples were previously published in Prat [13].
Nanostring results were then normalized following the
Nanostring Gene Expression Data Analysis Guide-
lines.
General transcriptional signatures associated with T-
cell activity in the tumor were obtained from different
publications [9,12,19,26]. Gene expression signatures
characteristic of different immune cell populations
were obtained from Davoli [19]. Those signatures with
less than 50% of the genes represented in the Nanos-
tring PanCancer Immune Profiling Panel were dis-
carded. A list of genes used in each signature is shown
in Table S3.
The value of each of these signatures per sample
was computed as the geometric mean of the expression
values of all genes included in the signature. Next, the
values of all samples for each signature were standard-
ized by subtracting the mean value of the signature in
the cohort and dividing by the standard deviation.
2.7. Statistical analysis
Mann–Whitney Wilcoxon (MWW) tests were per-
formed using the Statannot python library. MWW
tests comparing TMB and immune infiltration scores
across ICIs benefit groups were left-sided. MWW tests
comparing SCNAs burden across ICIs benefit group
were right-sided. Finally, MWW tests regarding TMB
or SCNAs burden differences across clinical features
were two-sided.
Survival analyses were performed using the lifelines
python package. Univariate Cox proportional hazards
models were built for each feature separately. Also,
multivariate models were built combining features of
interest. Additionally, multivariate models were strati-
fied by histology and smoking history of the patient.
Variables correlation. The relationship between ana-
lyzed features was assessed using both Spearman’s
rank and Pearson correlations.
2.8. Validation cohorts
The Non-Small Cell Lung Cancer MSKCC cohort
(NSCLC-MSK) [20] was downloaded from cBioPortal
[27] (https://www.cbioportal.org/study/summary?id=
nsclc_pd1_msk_2018).
Patients with available TMB, FGA (estimation of
SCNAs burden), and PD-L1 expression data were
selected and stratified into three groups based on their
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PFS following ICIs treatment (<6 months, 6-
18 months, or > 18 months of PFS). Patients with a
PFS < 18 months but with no confirmed progression
(censored) were discarded. Then, TMB, SCNAs bur-
den, and PD-L1 were compared between groups.
Additionally, TMB, FGA, and PD-L1 expression
was incorporated into a Cox proportional hazards
model together with sex, age, and smoking status.
Unlike the previous analysis, progression-free patients
with a PFS under 18 months were included. This
model was stratified by tumor histology.
A second cohort was used as further validation.
Data were downloaded from the supplementary mate-
rials of the publication [14]. Patients with both TMB
and PD-L1 data were selected and stratified into three
groups based on their PFS as described above. Next,
the distribution of TMB and PD-L1 expression
between these groups was compared.
3. RESULTS
3.1. Patients and clinical setting
We assembled a cohort of 47 patients diagnosed with
advanced NSCLC and treated with ICIs as monother-
apy. Detailed clinical description is shown in Table S1
and S2. 27 patients exhibited durable clinical benefit
defined as a progression-free survival (PFS) >
6 months, while 20 progressed within this period. Our
cohort included 15 patients who exhibited a
PFS > 18 months, exceeding 36 months in 8 cases,
and 6 of whom remained without signs of progression
at the time of closing this study (reaching 60 months
in 3 cases).
3.2. Tumor-intrinsic features and response to ICIs
We performed whole-exome sequencing (WES) from
tumor samples of all 47 patients and their paired-nor-
mal sample. After appropriate quality controls, 44
samples were found to be suitable for further analysis.
We determined the TMB for these 44 samples and cor-
related it with different clinical features including
histology, sex, smoking status, and drug’s target
(Fig. S1). As expected, patients with smoking history
presented significantly higher TMB than never smokers
(median 387 and 95, respectively; Mann–Whitney–Wil-
coxon test (MWW) P = 0.004).
We next interrogated the association between TMB
and response to ICIs. Patients who presented durable
clinical benefit (PFS > 6 months) had slightly higher
TMB than those with no clinical benefit (MWW,
P = 0.029) (Fig. 1A). Patients were then stratified into
three groups based on their PFS: no benefit (<
6 months), moderate (6-18 months), and long-term
benefit (> 18 months). When comparing TMB distribu-
tion across groups, patients with long-term benefit had
substantially higher TMB than those with moderate or
no benefit (MWW, P = 0.01 and 0.003, respectively)
(Fig. 1B), while no statistically significant differences
were observed between these two groups (Fig. 1B).
Additionally, Kaplan–Meier analysis of patients strati-
fied into TMB tertiles indicated that patients in the
upper tertile had longer PFS than those in the lower
one (log-rank test, P = 0.003) (Fig. 1C).
Somatic copy number alterations burden has also
been reported to influence ICIs response [17,19,28]. To
determine its importance in our cohort, we first inferred
SCNAs for those samples with enough tumor purity (40
samples, see methodology) and computed the sum of
the size of all altered regions of the genome. Then, we
related this score to patients’ PFS. No statistically sig-
nificant differences were observed when stratifying
patients into the three categories of benefit defined
above, even though we could observe that those with
clinical benefit tend to have lower SCNAs burden
(Fig. 1D,E). Indeed, Kaplan–Meier analysis dividing
patients into tertiles based on their tumor’s SCNAs bur-
den revealed that those in the upper tertile had statisti-
cally significant shorter PFS than those in the
intermediate and lower tertiles (log-rank test, P = 0.029
and 0.023, respectively) (Fig. 1F). These data suggest
that high levels of SCNAs are associated with decreased
PFS, while patients with moderate and low SCNAs bur-
den levels present no differences in response to ICIs.
Finally, we assessed whether mutations or copy
number alterations in individual genes were associated
Fig. 1. Tumor genomic characterization and response to ICIs. (A, B) Tumor mutational burden (TMB) distribution across groups of ICIs
benefit. Color indicates best response to ICIs (CR: complete response, PR: partial response, SD: stable disease, and PD: progressive
disease). (C) Kaplan–Meier plot dividing the cohort into TMB tertiles. (D, E) Somatic copy number alterations (SCNAs) burden distribution
across groups of ICIs benefit. Color indicates best response. (F) Kaplan–Meier plot survival curves dividing the cohort into SCNAs burden
tertiles. (G) Genomic alterations in selected genes. Columns and rows represent patients and genes, respectively. Mann–Whitney–Wilcoxon
tests have been used to determine differences between ICIs benefit groups (A, B, D, E). Log-rank tests have been used to determine
differences between TMB groups and between SCNAs groups (C, F). ns: 0.05 < P ≤ 1.0; *: 0.01 < P <0.05; **: 0.001 < P ≤ 0.01.
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with response (complete list of somatic alterations
Supplementary Tables S4 and S5). After appropriate
multiple-test correction, no alterations were found to
be significantly associated with response. We also
explored the distribution of somatic alterations in
known lung cancer-related genes and genes associated
with ICIs response (Fig. 1G). However, no single gene
was found to be significantly enriched in any of the
groups (data not shown).
3.3. Tumor immune-related transcriptional
signatures and response to ICIs
The amount and type of immune cells infiltrated within
the tumor have been suggested to influence response to
ICIs [9,12,13]. Thus, we obtained RNA expression data
from 22 patient’s biopsies by using a Nanostring panel
enriched in immune-related gene transcripts. We evalu-
ated whether transcriptional signatures previously asso-
ciated with activated T cells were related to ICIs
response [9,12,19,26]. Indeed, patients with clinical ben-
efit exhibited higher levels of these signatures compared
to those with lack of benefit; some were statistically sig-
nificant while others were close to significance (TEFF
score, MWW, P = 0.046) (Fig. 2A, Fig. S2A, S2B).
When stratifying patients into the three categories of
benefit, no differences were observed between moderate
and long-term benefit (Fig. 2B, Figs S2A, S2B), sug-
gesting that the results in Fig. 2A are not likely driven
only by long-term responders. Of note, this analysis has
limited statistical power due to sample size limitations
and should be taken cautiously.
Since the Nanostring panel encompasses a broad
range of gene transcripts, we analyzed immune cell-type-
specific signatures [19] and found that B cells, CD8 effec-
tive cells, natural killers, and T-reg were significantly
enriched in patients with benefit (MWW, P = 0.011,
0.035, 0.035, and 0.014, respectively), whereas M2
macrophages or other scores related to immunosuppres-
sive microenvironments were balanced between both
groups or even exhibited a trend toward being higher in
nonresponders (Fig. 2C,D, Fig. S2B, S2C).
Finally, we examined CD274 (PD-L1) expression
from the Nanostring data in these 22 patients and
found that high levels of CD274 expression were asso-
ciated with clinical benefit (MWW, P = 0.040)
(Fig. 2E). Notably, stratifying benefit into moderate
and long term revealed that high CD274 expression
levels were most evident in long-term responders com-
pared to patients with no benefit (MWW, P = 0.014)
(Fig. 2F). It is worth highlighting that for a few
patients with Nanostring data, PD-L1 expression by
immunohistochemistry was also available. In those,
correlation between CD274 and PD-L1 was high
(Spearman’s rank correlation, P = 0.0002, Fig. S2D).
3.4. Interplay between tumor-intrinsic and
tumor-extrinsic features
To better understand the determinants of response to
ICIs, we also studied the interplay between tumor-in-
trinsic and tumor microenvironment’s immune features.
We found that SCNAs burden negatively correlates
with most of the immune-related transcriptional signa-
tures evaluated but not with CD274 (PD-L1) expression,
while TMB appeared to be unrelated to all features ana-
lyzed (Fig. 3A, Fig. S3A, S3B). As TMB and SCNAs
burden are likely independent, we evaluated how their
combination related to ICIs benefit. Thereby, we repre-
sented patients’ TMB, SCNAs burden, and PFS and
then divided the cohort into four groups by using the
SCNAs burden and TMB means as thresholds. This
analysis revealed that almost all long-term responders
had above-average TMB and below-average SCNAs
burden, while patients whose tumors present opposite
characteristics were nonresponders (Fig. 3B). Also,
patients with moderate benefit tended to have either
high TMB or low SCNAs burden, but not both
(Fig. 3B). We observed three patients presenting high
TMB and low SCNAs burden who did not benefit from
ICIs treatment. Interestingly, in-depth inspection of
these patients revealed that one of them had prolonged
benefit despite radiological progression (499 days of
benefit after progression) and another presented a Large
cell neuroendocrine carcinoma (LCNEC) tumor known
to respond poorly to ICIs.
Furthermore, Kaplan–Meier analysis based on these
same four categories indicated that patients with high
TMB and low SCNAs exhibited statistically significant
longer PFS than those with low TMB and high
SCNAs burden, those with high TMB and high
SCNAs and near statistically significant than those
with low TMB and low SCNAs burden (log-rank test,
P = 0.006, 0.029, and 0.067, respectively) (Fig. 3C).
Notably, high SCNAs burden seems to curtail benefit’s
duration regardless of TMB levels, as none of the
patients with outstanding response exhibited high
SCNAs (Fig. 3C).
Finally, TMB and SCNAs burden were integrated
as continuous variables, together with patient’s sex
and ICIs’ target, in a multivariate Cox proportional
hazards model stratified by histology and smoking sta-
tus. This analysis indicated that both TMB and
SCNAs combined are significantly associated with ICIs
response even when correcting by potential confound-
ing factors (Fig. 3D).
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Fig. 2. Immune expression profiling of tumor’s microenvironment. (A, B) TEFF and cytotoxic score distribution across groups of ICIs benefit.
For each patient, the value of each signature has been computed as the geometric mean of the expression of all genes in the signature.
Next, for each of the scores, all values have been standardized. Color indicates best response to ICIs (CR: complete response, PR: partial
response, SD: stable disease, and PD: progressive disease). (C) Distribution of expression signatures belonging to four different immune cell
populations across groups of benefit. Values computed as in panel A. Color indicates best response to ICIs. (D) Representation of different
immune populations across 22 patients. Columns and rows correspond to patients and specific immune cell populations, respectively.
Patients have been clustered using a hierarchical clustering algorithm based on their degree of similarity considering amount and type of
tumor immune infiltration. (E) CD274 expression distribution according to indicated group of benefit. Color indicates best response. Mann–
Whitney–Wilcoxon tests have been used to determine differences between ICIs benefit groups (A, B, C, E, F); ns: 0.05 < P ≤ 1.0; *:
0.01 < P <0.05; **: 0.001 < P ≤ 0.01.
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Importantly, similar results were obtained when per-
forming the analysis above using patient’s overall sur-
vival (OS)—instead of PFS—as a measure of benefit
(Fig. S4A, S4B).
Altogether, these data indicate the utility of both
biomarkers to discriminate patients with benefit to ICIs
in a cohort of patients enriched in long-term responders.
3.5. Validation through analysis of publicly
available data
As stated in the introduction, NSCLC long-term
responders to ICIs remain poorly molecularly charac-
terized and indeed integrative studies using genomic
and transcriptomic data are almost nonexistent.
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Fig. 3. Interplay between biomarkers of response to ICIs. (A) Spearman correlation between indicated features. Color represents the
correlation coefficient. The P value of each correlation is shown within each cell. (B) Scatter plot representation of TMB and SCNAs burden.
Horizontal and vertical gray lines represent the SCNAs burden and TMB mean, respectively. Dot color represents the group of benefit. (C)
Kaplan–Meier plot survival curves dividing the cohort into four groups based on the quadrants defined in panel 3B. Long-rank tests have
been used to determine differences between TMB-SCNAs groups. ns: 0.05 < P ≤ 1.0; *: 0.01 < P <0.05; **: 0.001 < P ≤ 0.01. (D)
Univariate and multivariate Cox proportional hazards model for SCNAs burden, ICIs target, sex, and TMB. Multivariate analysis has been
stratified by histology and smoking history. Features represented in blue are statistically significant (P < 0.05).
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Nevertheless, we sought to validate some of our find-
ings by reanalyzing a publicly available cohort
(NSCLC-MSK) for which genomic data (by targeted
next-generation sequencing) as well as PD-L1 expres-
sion data (by IHC) were available [20]. Of note, both
TMB and SCNAs burden (referred to as Fraction of
Genome Altered (FGA) in the original manuscript)
were estimated from a gene panel, which owing to the
size of the fraction of the genome included in the panel
and the type of genes included (mostly cancer-related
genes) is likely less accurate than WES or whole-genome
sequencing (especially when estimating SCNAs burden).
We stratified patients into the three same categories
based on their PFS (no benefit, moderate, and long-
term benefit) as we did in Fig. 1B,E. As observed in
our cohort, patients with long-term benefit had sub-
stantially higher TMB than those with moderate or no
benefit (MWW, P = 0.036 and 0.012, respectively)
(Fig. 4A), while no statistically significant differences
were observed between these two groups (Fig. 4A).
Additionally, we observed that long-term responders
had substantially higher PD-L1 expression (MWW,
P = 0.013) and lower SCNAs burden (MWW,
P = 0.023) than patients with no benefit (Fig. 4B,C).
The integrative analysis performed on our cohort
(Fig. 3A) suggests the potential value of combining
TMB, SCNAs burden, and PD-L1 expression. In our
cohort, we did not build such model due to the
reduced number of patients with CD274 (PD-L1) gene
expression data. Nevertheless, we could create it using
the NSCLC-MSK cohort. Thus, we incorporated
TMB, SCNAs burden, and PD-L1 expression, together
with other clinically relevant features to a multivariate
Cox proportional hazards model, which was stratified
by tumor histology. Our analysis indicates that all
three features are statistically associated with patient’s
PFS (Fig. 4D).
Finally, the increased TMB and PD-L1 levels in
long-term responders were further validated using a
second independent cohort treated with PD-1 plus
CTLA-4 blockade [14] (Fig. S5A, S5B).
Thus, the analysis of two independent datasets con-
firms our findings, highlighting the importance of
TMB to discriminate long-term responders. Addition-
ally, we showed the value of combining TMB, PD-L1,
and SCNAs burden as complementary determinants of
ICIs response.
4. DISCUSSION
Advanced NSCLC treatment strategies have substan-
tially changed since the emergence of ICIs. However,
only a fraction of patients benefits from this type of
immunotherapy, and most that do eventually acquire
resistance. Thus, there is a need to find biomarkers to
































Fig. 4. NSCLC-MSK cohort analysis. (A)
TMB, (B) FGA (SCNAs burden), and (C)
PD-L1 distribution across groups of ICIs
benefit. Mann–Whitney–Wilcoxon tests
have been used to determine differences
between clinical benefit groups (A, B, C).
ns: 0.05 < P ≤ 1.0; *: 0.01 < P < 0.05. (D)
Multivariate Cox proportional hazards
model for FGA (SCNAs burden), age,
TMB, smoking status, sex, and PD-L1,
stratified by histology. Features
represented in blue are statistically
significant (P < 0.05).
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specifically those who will present a long-lasting
response which, despite a recent publication [8], remain
largely unexplored.
To this end, we gathered a new cohort of NSCLC
patients treated with ICIs enriched in long-term
responders and analyzed genomic and transcriptomic
features aiming to better understand the determinants
of ICI-associated long-term response. Additionally, we
validated our findings by reanalyzing public data from
previous studies [14,20].
The relevance of TMB as biomarker to predict
response upon ICIs treatment is under debate
[8,15,18,20,29–31]. We believe that our data shed light
on this topic, as we found that the association between
clinical benefit and TMB is mainly driven by patients
with long-term response (>18 months), whose TMB is
much higher than the rest of patients, while we did not
observe substantial differences regarding TMB between
patients with no or moderate clinical benefit. This
observation, originally based on our cohort, was fur-
ther validated by reanalyzing two publicly available
cohorts [14,20]. Thus, in an unselected cohort, in which
the proportion of individuals with long-lasting benefit
would be small, the association between TMB and ICIs
response could easily go unnoticed. Our data indicate
that TMB might be a biomarker of long-term response
(PFS > 18 months) rather than of durable clinical ben-
efit (PFS > 6 months). Thus, there is a subgroup of
patients who benefit from ICIs treatment (those with a
PFS between 6 and 18 months), but do not exhibit
higher TMB than those without benefit, a feature that
seems to be specific of long-term responders. These
patients, with moderate benefit, must present other fea-
tures that would explain this positive response to the
treatment.
In fact, we evaluated the influence of SCNAs burden,
which remains less studied particularly in advanced
NSCLC. Our data highlight its importance as determi-
nant of response to ICIs, as patients with high SCNAs
burden exhibited a poorer response than the rest. In
contrast, no response differences seem to exist between
patients with medium or low SCNAs burden. Alto-
gether it suggests a detrimental effect of high levels of
chromosomal aberrations—presumably chromosomal
instability—upon ICIs treatment, which could be at
least partially explained by its negative correlation with
immune infiltration as discussed below.
Furthermore, TMB and SCNAs are independent
biomarkers and our data indicate the value of combin-
ing both features to discriminate those patients who
will achieve sustained benefit upon ICIs treatment.
Beyond these features, other tumor genomic alter-
ations have been reported to be indicators of response
in previous studies, such as individual gene mutations
and copy number alterations [29,32,33]. However, we
could not identify a single gene associated with
response or long-term benefit after appropriate statisti-
cal correction; even though this might not be surpris-
ing as the inferred number of patients required to
identify individual genes was predicted to be substan-
tial [29]. The degree of homozygosis of human leuko-
cyte antigen (HLA) genes and the HLA allele types
has been also shown to influence ICIs response [34].
While we did study whether there was an association
between HLA homozygosis and response to ICIs in
our cohort, we did not observe a trend toward more
heterozygosis in any group (data not shown).
We also presented gene transcription data, which
indicates that T-cell activity-related transcriptional sig-
natures are associated with clinical benefit to ICIs,
consistent with previous reports [9,10,12,13]; however,
it does not seem to discriminate between moderate and
long-term response. Additionally, we identified specific
immune cell-type populations enriched in responders,
some of which (CD8, natural killers, B cells) have been
related to the ability of the immune system to elimi-
nate tumor cells [35,36]. Notably, a recent report
found that PD-L1 expression was the most reliable
biomarker associated with long-term overall survival
upon PD-1 blockade [8]. Consistent with this study,
our results evaluating CD274 (PD-L1) gene transcript
levels from a Nanostring panel indicate a similar
result. Similarly, we found that patients with long-last-
ing benefit following ICIs exhibited higher levels of
PD-L1 in two independent cohorts.
We also investigated the interplay between tumor-in-
trinsic features and immune infiltration. It is worth
highlighting that we found that immune-related signa-
tures negatively correlated with SCNAs burden as
reported from TCGA data [19], which could explain
why patients whose tumors bore high levels of chro-
mosomal aberrations responded poorly to ICIs. In
contrast to SCNAs burden and consistent with other
studies [8,11,20], our data indicate that TMB does not
correlate with immune-related transcriptional signa-
tures nor with PD-L1. It is worth mentioning that
CD274 (PD-L1) expression, in contrast to other
immune-related signatures, did not seem to correlate
with SCNAs burden. Tumors may evade the immune
system through different mechanisms such as express-
ing PD-L1 or by preventing infiltration of immune
cells within the tumor, thereby an elevated burden of
SCNAs might be indicative of the latter.
Thus, both SCNAs burden and PD-L1 expression
might provide complementary information, which in
combination with TMB can enhance our ability to
10 Molecular Oncology (2021) ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
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identify patients who will exhibit sustained response to
ICIs. In our cohort, we could not build a model
including the three features together due to sample size
limitations. Nevertheless, we could evaluate them in
the NSCLC-MSK cohort and we showed, using multi-
variate analysis, that the three factors are indeed sig-
nificantly associated with ICIs response.
Similarly, the relatively low number of patients with
expression data limits our capacity to discriminate
between medium and long-term benefit and curtails
the use of this data in survival analyses (i.e., multivari-
ate model). Thus, we could not assess the value of
combining these gene transcription-based scores
together with TMB to better identify patients with
long-term benefit.
Another limitation of our study is that we could not
evaluate intra-tumoral heterogeneity within the pri-
mary tumor [37], as well as possible differences
between primary tumor and metastases. Certainly,
analysis of multiple sites of the same primary tumor
and/or metastases would provide a higher accuracy
when estimating TMB, SCNAs burden, and tumor
immune infiltration. However, obtaining these samples
is undoubtedly challenging in advanced NSCLC
patients. Additionally, WES might not be the best
approach to determine SCNAs along the genome;
hence, other techniques such as low pass whole-gen-
ome sequencing could offer more accurate results.
Finally, our cohort is strongly enriched in patients
with long-term benefit upon ICIs treatment, allowing a
detailed study of this subgroup, which was the primary
aim of our study. Therefore, our cohort does not fully
recapitulate the clinical reality in advanced NSCLC, as
in a cohort of unselected patients, long-term ICIs
responders would be few. Nevertheless, we validated
our findings by analyzing two independent cohorts
with publicly data available.
5. CONCLUSION
Our data indicate that high TMB moderately associ-
ates with durable clinical benefit to ICIs, while it is
strongly correlated with long-term response. Con-
versely, high SCNAs burden is indicative of lack of
response. Additionally, patients who benefit from ICIs
treatment present higher levels of immune infiltration
signatures, even though this does not seem suggestive
of benefit’s duration. Additionally, CD274 expression
is particularly high in long-term responders. TMB is
independent of SCNAs burden or tumor immune infil-
tration, which are negatively correlated. Combining
TMB and SCNAs burden allows to discriminate
patients with ICI-associated long-term benefit (either
PFS or OS) better than each feature individually.
Notably, our observation that TMB is strongly
enriched in long-term responders to ICIs was validated
in two independent cohorts, suggesting that TMB
might be a biomarker of long-lasting benefit rather
than durable clinical benefit (6 months of PFS).
Finally, using the NSCLC-MSK cohort, we described
that TMB, SCNAs burden, and PD-L1 are signifi-
cantly associated with clinical benefit following ICIs
treatment.
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